Potential use of exenatide for the treatment of obesity

Bibliography

• Shai I, Schwarzfuchs D, Henkin Y, Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008;20(3):229-41
   Web of Science ®Google Scholar
• Eckel RH. Clinical practice. Nonsurgical management of obesity in adults. N Engl J Med 2008;358(18):1941-50
   PubMed Web of Science ®Google Scholar
• James WP, Caterson ID, Coutinho W, Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363(10):905-17
   PubMed Web of Science ®Google Scholar
• Wright SM, Aronne LJ. Obesity in 2010: the future of obesity medicine: where do we go from here? Nat Rev Endocrinol 2011;7(2):69-70
   PubMed Web of Science ®Google Scholar
• Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity. Clin Pharmacol Ther 2011;90(1):40-51
   PubMed Web of Science ®Google Scholar
• Rucker D, Padwal R, Li SK, Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335(7631):1194-9
   PubMed Web of Science ®Google Scholar
• Hussain SS, Bloom SR. The pharmacological treatment and management of obesity. Postgrad Med 2011;123(1):34-44
   PubMed Web of Science ®Google Scholar
• Holst JJ, Schwartz TW, Lovgreen NA, Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. Int J Obes 1983;7(6):529-38
   PubMed Web of Science ®Google Scholar
• Naslund E, Gryback P, Backman L, Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998;43(5):945-52
   PubMed Web of Science ®Google Scholar
• Verdich C, Toubro S, Buemann B, The role of postprandial releases of insulin and incretin hormones in meal-induced satiety–effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001;25(8):1206-14
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Krarup T, Sonne J, Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88(6):2706-13
   PubMed Web of Science ®Google Scholar
• Ranganath L, Norris F, Morgan L, Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids. Clin Sci (Lond) 1999;96(4):335-42
   PubMed Web of Science ®Google Scholar
• Ranganath LR, Beety JM, Morgan LM, Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996;38(6):916-19
   PubMed Web of Science ®Google Scholar
• Rask E, Olsson T, Soderberg S, Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001;24(9):1640-5
   PubMed Web of Science ®Google Scholar
• Larsen PJ, Vrang N, Tang-Christensen M. Central pre-proglucagon derived peptides: opportunities for treatment of obesity. Curr Pharm Des 2003;9(17):1373-82
   PubMed Web of Science ®Google Scholar
• Navarro M, Rodriquez de Fonseca F, Alvarez E, Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 1996;67(5):1982-91
   PubMed Web of Science ®Google Scholar
• Rodriquez de Fonseca F, Navarro M, Alvarez E, Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 2000;49(6):709-17
   PubMed Web of Science ®Google Scholar
• Szayna M, Doyle ME, Betkey JA, Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000;141(6):1936-41
   PubMed Web of Science ®Google Scholar
• Van Dijk G, Thiele TE, Donahey JC, Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain. Am J Physiol 1996;271(4 Pt 2):R1096-100
   PubMed Web of Science ®Google Scholar
• van Dijk G, Thiele TE, Seeley RJ, Glucagon-like peptide-1 and satiety. Nature 1997;385(6613):214
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-100
   PubMed Web of Science ®Google Scholar
• Buse JB, Klonoff DC, Nielsen LL, Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007;29(1):139-53
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24(1):275-86
   PubMed Web of Science ®Google Scholar
• Barnett AH, Burger J, Johns D, Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29(11):2333-48
   PubMed Web of Science ®Google Scholar
• Bergenstal R, Lewin A, Bailey T, Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 2009;25(1):65-75
   PubMed Web of Science ®Google Scholar
• Buse JB, Drucker DJ, Taylor KL, DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33(6):1255-61
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-35
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374(9683):39-47
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372(9645):1240-50
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143(8):559-69
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083-91
   PubMed Web of Science ®Google Scholar
• Moretto TJ, Milton DR, Ridge TD, Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30(8):1448-60
   PubMed Web of Science ®Google Scholar
• Nauck MA, Duran S, Kim D, A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50(2):259-67
   PubMed Web of Science ®Google Scholar
• Bischoff LA, Jabbour SA, Miller JL. Exenatide once weekly in type 2 diabetes mellitus. Expert Opin Pharmacother 2011;12(8):1297-303
   PubMed Web of Science ®Google Scholar
• Madsbad S, Kielgast U, Asmar M, An overview of once-weekly GLP-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Taylor K, Gurney K, Han J, Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011;11:9
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Kim DD, Shen L, Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62(2):173-81
   PubMed Web of Science ®Google Scholar
• Dore DD, Bloomgren GL, Wenten M, A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011;13(6):559-66
   PubMed Web of Science ®Google Scholar
• Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25(4):1019-27
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies–review of the scientific evidence. J Clin Endocrinol Metab 2011;96(7):2027-31
   PubMed Web of Science ®Google Scholar
• Ratner RE, Maggs D, Nielsen LL, Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006;8(4):419-28
   PubMed Web of Science ®Google Scholar
• Bunck MC, Corner A, Eliasson B, Effects of Exenatide on Measures of {beta}-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care 2011;34(9):2041-7
   PubMed Web of Science ®Google Scholar
• Apovian CM, Bergenstal RM, Cuddihy RM, Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010;123(5):468-e9-17
   PubMed Web of Science ®Google Scholar
• Bunck MC, Diamant M, Eliasson B, Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010;33(8):1734-7
   PubMed Web of Science ®Google Scholar
• Elkind-Hirsch K, Marrioneaux O, Bhushan M, Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93(7):2670-8
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Klaff LJ, Schwartz S, Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33(6):1173-5
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, Ramos-Zavala MG. Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome. Metab Syndr Relat Disord 2011;9(1):31-4
   PubMed Web of Science ®Google Scholar
• Astrup A, Rossner S, Van Gaal L, Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374(9701):1606-16
   PubMed Web of Science ®Google Scholar
• Lutz TA. Pancreatic amylin as a centrally acting satiating hormone. Curr Drug Targets 2005;6(2):181-9
   PubMed Web of Science ®Google Scholar
• Lutz TA. Amylinergic control of food intake. Physiol Behav 2006;89(4):465-71
   PubMed Web of Science ®Google Scholar
• Hollander P, Maggs DG, Ruggles JA, Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004;12(4):661-8
   PubMedGoogle Scholar
• Ravussin E, Smith SR, Mitchell JA, Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009;17(9):1736-43
   PubMed Web of Science ®Google Scholar